2022
DOI: 10.1038/s41435-021-00161-5
|View full text |Cite|
|
Sign up to set email alerts
|

Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma

Abstract: Immunogenic cell death (ICD) has emerged as a key component of therapy-induced anti-tumor immunity. Over the past few years, ICD was found to play a pivotal role in a wide variety of novel and existing treatment modalities. The clinical application of these techniques in cancer treatment is still in its infancy. Glioblastoma (GBM) is the most lethal primary brain tumor with a dismal prognosis despite maximal therapy. The development of new therapies in this aggressive type of tumors remains highly challenging … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
25
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
1
1

Relationship

3
7

Authors

Journals

citations
Cited by 41 publications
(25 citation statements)
references
References 178 publications
0
25
0
Order By: Relevance
“…ICD, a novel concept linking dying cancer cells with the immune system, is a form of cell death that leads to the regulation and activation of the immune response ( 36 ). The concomitant ROS production and endoplasmic reticulum stress within the ICD process activate the exposure and release of DAMPs in the tumor microenvironment, which is able to potentiate immune response ( 37 ). Currently, there is no study reporting the prognosis and immunotherapy of patients with GBM based on ICD gene signatures.…”
Section: Discussionmentioning
confidence: 99%
“…ICD, a novel concept linking dying cancer cells with the immune system, is a form of cell death that leads to the regulation and activation of the immune response ( 36 ). The concomitant ROS production and endoplasmic reticulum stress within the ICD process activate the exposure and release of DAMPs in the tumor microenvironment, which is able to potentiate immune response ( 37 ). Currently, there is no study reporting the prognosis and immunotherapy of patients with GBM based on ICD gene signatures.…”
Section: Discussionmentioning
confidence: 99%
“…US-based BBB disruption, therefore, can both enhance CNS penetration of PTX and improve survival [ 176 ]. Additionally, paclitaxel has been recently identified as an inducer of immunogenic cell death, a form of cell death that directly promotes antitumor immunity [ 176 ], and as a result, BBB-mediated delivery of paclitaxel may enhance immunotherapies for GBM [ 177 ].…”
Section: Making Things Hot: Promoting T-cell Infiltration Into Gbmmentioning
confidence: 99%
“…Immunogenic cell death (ICD) is a more recently discovered cell death modality that involves specific, timed changes to the cell surface (CRT expression) followed by release of soluble DAMPs (e.g., HMGB1, HSP). Importantly, this increases the immunogenicity of dying/dead cancer cells, and has the ability to potentiate adaptive immune responses and target residual cancer cells/tissues [13,14].…”
Section: Introduction 1oncolytic Virusesmentioning
confidence: 99%